-
Robust Growth in Biological Drug CDMO Market (2024-2032): Industry Insights, SWOT Analysis, Market Size and Share
27 Nov 2024 11:31 GMT
… 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The Biological Drug CDMO (Contract Development … Hepalink,Pharmaron
Market Split by Types:
• Innovative Drug
• Listed Patent Drugs … Biological Drug Contract … 𝐃𝐫𝐮𝐠 𝐂𝐃𝐌𝐎 𝐌𝐚𝐫𝐤𝐞𝐭:
The Biological Drug CDMO (Contract Development and …
-
Hong Kong police investigate email scam following German pharmaceutical firm’s report it was swindled out of more than RM15.34mil
16 Jan 2024 07:57 GMT
… involved Hong Kong. Separately, the Shenzhen Hepalink Pharmaceutical Group, listed in Hong Kong … its wholly owned subsidiary – Techdow Pharma Italy – was suspected to have … about €11.7mil (RM59.83mil). “[Shenzhen Hepalink] promptly reported the incident to …
-
Hong Kong police investigate email scam following German pharmaceutical firm’s report it was swindled out of more than €3 million
16 Jan 2024 02:08 GMT
… involved Hong Kong.
Separately, the Shenzhen Hepalink Pharmaceutical Group, listed in Hong Kong … its wholly owned subsidiary – Techdow Pharma Italy – was suspected to have … involved about €11.7 million.
“[Shenzhen Hepalink] promptly reported the incident to …
-
Shenzhen Hepalink Pharmaceutical Group (OTCMKTS:SHEZF) Downgraded by The Goldman Sachs Group to Sell
05 Oct 2023 14:07 GMT
…
Shenzhen Hepalink Pharmaceutical Group Stock Performance
Shenzhen Hepalink Pharmaceutical Group Company Profile
(Get Free Report)
Shenzhen Hepalink Pharmaceutical … analysts' ratings for Shenzhen Hepalink Pharmaceutical Group and related companies with …
-
Growing Emphasis on Generic Drug Manufacturing Boosts Active Pharmaceutical Ingredient Market to US$ 300.2 Billion by 2033: Persistence Market Research
25 Jul 2023 18:33 GMT
… and advancements in drug development technologies have been … Rising adoption of generic drugs and biosimilars.
Technological … Rising concerns over counterfeit drugs.
Market Trends
Increased … Roche Ltd, GlaxoSmithKline plc, Hepalink Group Lonza, Merck …
-
Global Active Pharmaceutical Ingredients Market Outlook & Forecast 2023-2028 - ResearchAndMarkets.com
25 Jul 2023 10:16 GMT
… other brand-name drugs. Moreover, generic drugs are often the … generic drug supply chain.
COMPETITIVE LANDSCAPE
The active pharmaceutical ingredients … -La Roche
GLENMARK PHARMACEUTICALS LTD.
Lupin
Shenzhen Hepalink Pharmaceutical Group
KEY QUESTIONS …
-
OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab
28 Mar 2023 08:03 GMT
… ;), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the … in 2003, OEP provides prescription drugs, cancer drugs, nutrition and healthcare for young …
-
Active Pharmaceutical Ingredients API Market Size, Share, Industry Outlook & Global Forecast To 2031
07 Jul 2022 11:26 GMT
… manufacturers
• Type of drugs
• Synthesis Type
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTS
…
Market Segmentation by Type of drugs
• Prescription
• Over the … GmbH
• BASF SE
• Lupin
• Shenzhen Hepalink Pharmaceutical Group Ltd.
• Abbott
• Biocon
• …
-
Global Active Pharmaceutical Ingredient Market (2021 to 2026) - Featuring AbbVie, Cipla and Pfizer Among Others'
16 Feb 2022 23:10 GMT
… rising investments of the pharmaceutical companies in API drugs also benefit market … .2 Regulatory Policies and Unfavourable Drug Price Control Policies4.3 Opportunities4 … Holding AG13.16 Sanofi13.17 Shenzhen Hepalink Pharmaceutical Co., Ltd.13.18 Sun …
-
Insights on the Active Pharmaceutical Ingredient Global Market to 2026 - Emergence of Biosimilars Market Presents Opportunities - ResearchAndMarkets.com
15 Feb 2022 15:40 GMT
… investments of the pharmaceutical companies in API drugs also benefit market … (AI) Adoption for Drug Discovery
Challenges
Drug Price Control Policies Across … Holding AG
Sanofi
Shenzhen Hepalink Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva …
About
© 1995-2025